Axotomy-induced neurotrophic withdrawal causes the loss of phenotypic differentiation and downregulation of NGF signalling, but not death of septal cholinergic neurons by Lazo, Oscar M et al.
RESEARCH ARTICLE Open Access
Axotomy-induced neurotrophic withdrawal
causes the loss of phenotypic differentiation and
downregulation of NGF signalling, but not death
of septal cholinergic neurons
Oscar M Lazo
1, Jocelyn C Mauna
1,3, Claudia A Pissani
1, Nibaldo C Inestrosa
2, Francisca C Bronfman
1*
Abstract
Background: Septal cholinergic neurons account for most of the cholinergic innervations of the hippocampus, playing
a key role in the regulation of hippocampal synaptic activity. Disruption of the septo-hippocampal pathway by an
experimental transection of the fimbria-fornix drastically reduces the target-derived trophic support received by
cholinergic septal neurons, mainly nerve growth factor (NGF) from the hippocampus. Axotomy of cholinergic neurons
induces a reduction in the number of neurons positive for cholinergic markers in the medial septum. In several studies,
the reduction of cholinergic markers has been interpreted as analogous to the neurodegeneration of cholinergic cells,
ruling out the possibility that neurons lose their cholinergic phenotype without dying. Understanding the mechanism
of cholinergic neurodegeneration after axotomy is relevant, since this paradigm has been extensively explored as an
animal model of the cholinergic impairment observed in neuropathologies such as Alzheimer’s disease.
The principal aim of this study was to evaluate, using modern quantitative confocal microscopy, neurodegenerative
changes in septal cholinergic neurons after axotomy and to assess their response to delayed infusion of NGF in rats.
Results: We found that there is a slow reduction of cholinergic cells labeled by ChAT and p75 after axotomy.
However, this phenomenon is not accompanied by neurodegenerative changes or by a decrease in total neuronal
number in the medial septum. Although the remaining axotomized-neurons appear healthy, they are unable to
respond to delayed NGF infusion.
Conclusions: Our results demonstrate that at 3 weeks, axotomized cholinergic neurons lose their cholinergic
phenotype without dying and down-regulate their NGF-receptors, precluding the possibility of a response to NGF.
Therefore, the physiological role of NGF in the adult septal cholinergic system is to support phenotypic
differentiation and not survival of neurons. This evidence raises questions about the relationship between
transcriptional regulation of the cholinergic phenotype by retrograde-derived trophic signaling and the
transcriptional changes experienced when retrograde transport is impaired due to neuropathological conditions.
Background
Basal forebrain cholinergic neurons (BFCN) account for
most of the cholinergic innervation of the hippocampus
and cortical mantle, and have a key role in the regula-
tion of synaptic activity and modulation of memory and
attention in rodents, primates and humans [1-5].
The physiology of septal cholinergic neurons is regu-
lated by the trophic support offered by their target, the
hippocampus. Disconnection of septal cholinergic neu-
rons from their target by an experimental transection of
the fimbria-fornix, reduces the number of neurons posi-
tive for cholinergic markers such as choline acetyl trans-
ferase (ChAT) [1,6-13]. One of the best-studied trophic
factors for septal cholinergic neurons is nerve growth
factor (NGF). Levels of NGF mRNA and protein are
consistently detected in the hippocampal formation and
cortex. In addition, it is well established that NGF is
* Correspondence: fbronfman@bio.puc.cl
1Department of Physiology, Neurobiology Unit, Center of Ageing and
Regeneration (CARE), Nucleus Millennium in Regenerative Biology (MINREB),
Faculty of Biological Sciences, Pontificia Universidad Catolica de Chile,
Alameda 340, CP 8331010, Santiago, Chile
Lazo et al. Molecular Neurodegeneration 2010, 5:5
http://www.molecularneurodegeneration.com/content/5/1/5
© 2010 Lazo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.retrogradely transported from the hippocampus to the
septal area and that intracerebroventricular application
of NGF or intracerebral transplant of NGF-releasing
cells prevents the reduction in the proportion of neu-
rons positive for cholinergic markers after axotomy
[14,15,7,12,16-18].
The mechanisms of cholinergic neurodegeneration
after axotomy are poorly characterized. Most of the stu-
dies performed have considered the loss of ChAT, acetyl
cholinesterase (AChE) or p75 neurotrophin receptor
(p75) immunoreactivity as an analogue of neurodegen-
eration [19-22], ruling out the possibility that neurons
lose their cholinergic phenotype without dying.
Septal cholinergic neurons express two different types
of receptors for NGF: the tyrosine kinase receptor TrkA
(TrkA), which specifically binds NGF; and the p75 neu-
rotrophin receptor (p75), which binds all neurotrophins.
Together, TrkA and p75 activate pro-survival gene
expression and influence growth [23]. Conversely, p75
signaling mediates neuronal death by apoptosis in differ-
ent neuronal systems, including neurodegenerative mod-
els such as corticospinal axotomy and seizure-induced
apoptosis of septal cholinergic neurons [24-29]. Activa-
tion of NGF receptors up-regulates several cholinergic-
specific genes, such as the high-affinity choline transpor-
ter and the acetylcholine synthesizing enzyme ChAT,
which share a common gene locus with the vesicular
acetylcholine transporter (VAChT) [30-33].
Axotomy-induced cholinergic decay in the basal fore-
brain has been explored as an animal model for cogni-
tive decline due to cholinergic impairment, similar to
that observed in aging and neuropathologies such as
Alzheimer’s disease (AD) [34,35]. Due to its role as a
neurotrophic factor for cholinergic neurons, NGF gene
therapy is currently in phase 1 clinical trial for AD treat-
ment [12,36-39].
The principal aim of this research was to re-evaluate,
using modern quantitative confocal microscopy, neuro-
degenerative changes in septal cholinergic neurons after
axotomy and to assess their response to delayed infusion
of NGF in rats. To pursue this goal, we have performed
a stereological analysis of the rat septal area, using
quantitative double- and triple-labeling confocal micro-
scopy analysis of axotomized brains with different cell
markers and neurodegenerative labels at different time-
points after axotomy. Furthermore, we have assessed the
response of cholinergic neurons to delayed infusion of
NGF three weeks after axotomy.
As shown before, we found that there is a slow reduc-
tion in the number of immunoreactive cholinergic cells
after axotomy [6,40]. However, this phenomenon is not
accompanied by neurodegenerative changes or a
decrease of total neuronal number in the medial sep-
tum. Although the remaining axotomized-cells appear
healthy, they are unable to respond to delayed NGF
infusion. These results demonstrate that axotomized
cholinergic neurons down-regulate their NGF receptors,
precluding the possibility of a response to NGF.
Our results suggest that the physiological role of NGF
in the adult septal cholinergic system is to support phe-
notypic differentiation and not neuron survival. This evi-
dence raises the question of how the connection with
the target regulates the transcription of cholinergic mar-
kers in vivo and of which other factors could re-induce
the cholinergic phenotype when retrograde transport is
impaired due to neuropathological conditions such as
AD and Down syndrome [38,41,42].
Results
Expression profile of ChAT and p75 immunopositive
septal cholinergic neurons after axotomy of the fimbria-
fornix: a time course study
It is well established that after two weeks of unilateral
axotomy of the fimbria-fornix, the number of ChAT-
positive neurons ipsilateral to the lesion decreased to
about 30% as compared to the contralateral side
[8,10,13,43]. To quantify cholinergic cell loss, we used
two different antibodies against well-established choli-
nergic markers, ChAT and p75. We found a similar
slow reduction in ChAT and p75 immunopositive cells
as well as diminished acetyl cholinesterase (AChE) fiber
staining in the hippocampus (Figure 1). We observed
that the number of cells labeled with ChAT or p75
decreased with similar kinetics over time (7 to 21 days
after axotomy). However, there were always more cells
labeled with p75, suggesting that some cholinergic cells
had lost ChAT expression but continued expressing p75
(Figure 1C).
This finding was supported by quantitative confocal
studies where both ChAT and p75 were labeled in the
same section and the number of cells that were co-
labeled with both proteins was quantified. On the non-
axotomized side, co-localization between the two labels
was about 90%, whereas 14 days after the lesion, just
60% of the neurons labeled with p75 were also positive
for ChAT (Figure 2). In the septal nucleus, there are
also GABAergic neurons that could be re-expressing
p75 due to the axotomy. In a triple immunofluorescence
with ChAT, p75 and parvalbumin ‘ac o m m o n l yu s e d
GABAergic marker [44,45]- there was a non-significant
number of cells co-labeled with parvalbumin and p75
(Figure 3), ruling out the possibility that the neurons
expressing just p75 are GABAergic.
Septal cholinergic neurons do not degenerate through
apoptotic cell death after axotomy
p75 is an apoptotic receptor that mediates cell death of
cholinergic neurons in other paradigms [27,46]. However,
cholinergic neurons from p75 knockout mice are not
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neurons after axotomy [19], suggesting that p75 does not
play a role in cholinergic neurodegeneration after axot-
omy or that there is no death of cholinergic cells after
the fimbria-fornix lesion. To further support this possibi-
lity, we performed triple immunostaining against ChAT,
p75 and p53 or cleaved caspase-3 in rat brain sections
starting from day one up to two weeks after axotomy.
Although there were positive reactions for cleaved cas-
pase-3 or p53 in the septal nucleus after axotomy, they
did not co-localize with ChAT, p75 or the general neuro-
nal marker NeuN (Figure 4A, B, C). In addition, neurons
were not labeled with Fluorojade C, a well-known marker
of degenerating neurons [27,47] (Figure 4D). To further
identify the nature of the cells that were positive for
cleaved caspase-3 (Figure 4C), double immunostaining
was performed with NeuN [48,49] and the glial fibrillary
acidic protein (GFAP) to label astroglia. We could clearly
identify the astroglia as the cell type co-localizing with
cleaved caspase-3 (Figure 4C).
To standardize the immunostaining of cleaved cas-
pase-3 and p53, we induced cell death by injecting
H2O2 to the medial septum. In these conditions, cleaved
caspase-3 and p53 clearly labeled damaged neurons as
indicated by their co-localization with altered Neuro-
trace labeling (Additional file 1). Neurotrace is a fluores-
cent Nissl staining that only labels neurons and does
not co-localize with markers of different glial cells such
as astro, micro or oligodendroglia (Additional file 2).
There is no loss of neurons in the medial septum three
weeks after axotomy
In order to determine whether there is a non-apoptotic
neuronal degeneration after axotomy in the septal
nucleus, triple immunostaining with two neuronal mar-
kers -Neurotrace and NeuN- plus the astroglial marker
GFAP was performed in sections of 3-week axotomized
rat brains and control brains. The total number of neu-
rons in the septal nucleus was quantified as defined in
Figure 5. Our analysis indicated that there was no differ-
ence between the total numbers of neurons from the
contralateral vs. ipslateral side to the lesion (Figure 5). It
is still possible that the axotomy performed to the rat
brain may have an effect in the total number of neurons
in the contralateral side to the lesion. To address this
point, we have quantified the total number of neurons
in the medial septum -as define in Figure 5- in a healthy
brain comparing the left and the right sides of the med-
ial septum. We found, no differences in the total num-
ber of neurons between the left and the right sides of
healthy brains nor differences between these numbers
and the numbers of neurons found in lesioned brains
(Table 1). These results, together with the lack of
cleaved caspase-3, p53 and Fluorojade C staining 3
weeks after axotomy, strongly support the notion that
axotomy of the fimbria-fornix does not induce neuronal
death in the medial septum. Our results are also consis-
tent with the study of van der Zee and Hagg in p75
knockout (KO) mice. The authors studied the potential
participation of p75 in the death of axotomized choli-
nergic cells [19], and found that the absence of p75
does not prevent septal ChAT-positive cell loss. How-
ever, these results should be taken with caution, since
Figure 1 Effect of septo-hippocampal pathway axotomy in
cholinergic septal neurons. A, Light microscopy of coronal
sections stained for AChE 3 or 21 days after lesion procedure,
showing the early effect of axotomy in cholinergic projections
towards the hippocampus. Twenty-one days after axotomy, AChE-
positive terminals are strongly reduced in the ipsilateral side of the
lesion, as compared to the contralateral side (scale bar 1 mm).
Inferior panels, magnification inset of AChE-positive neurites in
dentate gyrus (scale bar 200 μm). B, Light microscopy of
immunohistochemistry anti-ChAT in coronal sections, showing the
effects of the axotomy in cell bodies of cholinergic septal neurons,
3 or 21 days after axotomy. Twenty-one days after the lesion, the
number of ChAT-positive neurons is clearly reduced on the
ipsilateral side of the medial septum (CL, contralateral; IL, ipsilateral.
Scale bar: 1 mm). C, Time course of ChAT- and p75-positive neuron
loss after axotomy. The graph shows the quantification of ChAT- or
p75-immunopositive neurons in the medial septum from serial
sections of brains at 3, 7, 14 and 21 days after the lesion. Note that
the numbers of ChAT- and p75-immunopositive cells decay with
similar kinetics but with a different slope between 7-14 days.
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microscopy of double-immunofluorescence anti-ChAT/anti-p75 reveals an increase in the number of neurons that are positive only for p75 at
different times after the axotomy. The superior panel is a panoramic view of the medial septum at 14 days after axotomy (scale bar: 1 mm). The
central and inferior panels are magnification insets (scale bar: 200 μm) of neurons contralateral and ipsilateral to the lesioned side, showing p75-
positive and ChAT-negative cells as indicated by the white arrows. B, The graph shows the percentage of total septal neurons expressing p75
that are p75-positive and ChAT-negative at 1, 3, 7 or 14 days after axotomy. Black bars represent the control side of the septum and white bars
represent the side ipsilateral to the lesion. Asterisk indicates significance level p < 0.05.
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p75 [50].
Response of axotomized septal neurons to delayed NGF
infusion
It is possible that the neurons that survive after axotomy
are still able to re-express the cholinergic markers if
trophic support is restored. Normally, axotomized choli-
nergic cells respond to NGF when the infusion of NGF
is concurrent with lesion surgery, as shown in Figure 6A
and described previously [6,20,40]. However, when NGF
was infused 3 weeks post-axotomy, neurons did not
respond and there were no increase in cholinergic cell
n u m b e r ,a si so b s e r v e dw h e nN G Fi si n f u s e ds i m u l t a -
neously to the lesion (Figure 6B). This correlates with
the fact that there is a reduction in the number of
TrkA-positive cells on the ipsilateral side, and all
remaining TrkA-positive cells are also ChAT positive
(Figure 6C). This suggests that the lack of response to
NGF is due to down-regulation of TrkA. The effect is
not explained by an incomplete diffusion of NGF to the
i p s i l a t e r a ls i d eo ft h es e p t u m ,s i n c et h e r ea r en e u r o n s
that are clearly positive for NGF: they show a punctate
pattern of staining, which is consistent with receptor-
mediated NGF uptake (Figure 6A, B). These results are
apparently different from those reported by Hagg and
colleagues [19,40] in mice. They found a small recovery
of ChAT immunopositive cells in the ipsilateral side
after delayed NGF treatment, in comparison to
untreated animals. However, in agreement with our
findings, van der Zee and Hagg observed that a signifi-
cant number of neurons (60%) were not capable of
responding to a delayed NGF infusion paradigm.
Discussion
In the present study, we report the response of basal fore-
brain cholinergic cells to axotomy based on the use of
time-course analyses, multiple immunostainings and
quantitative confocal microscopy. Our results establish
that cholinergic cells do not respond to disconnection of
their target, as induced by axotomy, with apoptotic cell-
death, but rather with down-regulation of the neurotrans-
mitter-synthesizing enzyme ChAT and NGF receptors. As
opposed to other nervous system injury models, such as
corticospinal and olfactory bulb axotomy and kainic acid-
induced cytotoxicity [27,29,51], p75 receptor does not play
a role in axotomy-induced cholinergic cell neurodegenera-
tion. Of note, like septal cholinergic cells, Purkinje cells in
the cerebellum are also resistant to axotomy [52]. We are
yet far from explaining the differences in the response to
axotomy between cholinergic and Purkinje neurons and
cortico-spinal and olfactory bulb neurons. One possibility
is that cholinergic neurons became resistant to the with-
drawal of neurotrophic factor, as postulated by Snider [53]
for sensory neurons. It is well established that during
development, or in neonates, axotomy or neurotrophic
deprivation induces apoptotic cell death of dorsal root
ganglia (DRG) neurons [54]. However, adult DRGs ‘as
opposed to embryonic DRGs- differentially express Del-
taNp73a, a pro-survival protein related to the p53 family
[55]. The expression of this protein renders cells resistant
to axotomy or neurotrophic factor withdrawal. Another
gene involved in protection of neurons after injury is the
heat shock protein Hsp27, which directly or indirectly acti-
vates the Akt survival pathway. The expression of Hsp27
inhibits JNK-mediated apoptosis in superior cervical
Figure 3 p75-positive and ChAT-negative neurons are not GABAergic. Confocal microscopy of triple-immunofluorescence anti-ChAT/anti-
p75/anti-parvalbumin shows no significant colocalization of GABAergic marker and p75. Left, a panoramic view of the medial septum (scale bar:
1 mm) and panel showing a magnification inset of a representative group of neurons from triple-labeled sections (scale bar: 300 μm).
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marker), GFAP (astroglial marker) and activated Caspase-3 shows no colocalization of the apoptotic marker with neurons at different time points
(1, 3, 7, 14 days) after axotomy. There is an increase in the number of cells that are immunopositive for activated caspase-3 with time. The
correlation between GFAP and activated Caspase-3 suggests that astrocytes are undergoing apoptosis (scale bar: 50 μm). B, Triple-
immunofluorescence against ChAT, p75 and p53, shows no colocalization of p53 (an early apoptotic marker) with p75- or ChAT-immunopositive
neurons in the brains of axotomized rats 14 days after the axotomy. Confocal microscopy (scale bar: 50 μm). Triple-immunofluorescence against
ChAT, p75 and activated caspase-3 shows no colocalization of activated Caspase-3 and p75 or ChAT immunopositive neurons after 14 days of
axotomy. Confocal microscopy (scale bar 50 μm). C, Axotomized septal neurons are not labeled with Fluorojade C (a specific staining for
degenerating neurons). Superior panel, a brain section from a rat injected in medial septum with 100 mM H2O2 was stained with Neurotrace
and Fluorojade C as a positive control. The arrow indicates a degenerating neuron. Center panel, double-labeling with Neurotrace and
Fluorojade in a brain section from an untreated rat. Inferior panel shows no colocalization of Neurotrace and Fluorojade C in medial septal
neurons 14 days after axotomy (scale bar 50 μm).
Figure 5 There is no difference between the number of septal neurons when comparing the ipsilateral and contralateral regions of
brains 21 days after axotomy. A, Left, confocal microscopy of triple labeling for Neurotrace (red), NeuN (green) and GFAP (blue) from the
septal region of a lesioned brain. In order to assure that we were counting only neurons, we used two neuronal markers and an astrocytic
marker (GFAP). Right, inset magnification of a neuron (scale bar: 80 μm) showing the Neurotrace and NeuN labeling profiles. B, Diagram
illustrating the area of the medial septum (MS) that was considered for the quantification of cholinergic or total number of neurons (adapted
from Rat Brain Atlas [65]). Each side of the total area was divided to 4 fields and then photographed and manually quantified. The anatomical
landmarks used to define the MS are also indicated (see Experimental Methods). cc, corpus callosum; LV, lateral ventricle; aca, anterior
commissure. C, Quantification of p75-positive, ChAT-positive and total septal neurons. Comparison of the number of septal neurons on
contralateral and ipsilateral sides shows differences in the numbers of p75- and ChAT-immunopositive neurons, but no significant difference in
total number of neurons (n = 5; Student’s t-test, p > 0.001, ± SD) 21 days after axotomy.
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interesting to study whether adult cholinergic cells express
DeltaNp73 and/or Hsp27. As mentioned above, other
adult neurons such as corticospinal neurons are not resis-
tant to axotomy and die in a p75-dependent fashion, prob-
ably because they fail to express any of the
abovementioned survival programs after injury [29,58].
One unexpected observation of our study was that only
GFAP-positive cells were immunopositive for cleaved cas-
pase-3. GFAP positive cells appear hypertrophic and
strongly stained in the whole tissue, thus revealing a gen-
eralized astrogliosis. This reaction may account for a glo-
bal inflammatory response to the lesion which may cause
apoptosis of astrocytes, as has been reported in other
injury models or in neurodegenerative diseases [59]. It is
interesting that apoptotic cell death in the septal nucleus
after axotomy was previously reported by electron micro-
scopy studies [21]. However, the quality of the microscopy
precludes discrimination of the cell type. Therefore, it is
possible that the apoptotic septal cells mentioned in this
study are glial cells rather than neurons.
Disruption of the connection between septal choliner-
gic cells and the hippocampus results in down-regula-
tion of ChAT, but not neuronal death. A consequence
of this is that the basal forebrain cholinergic cells
affected during aging and in pathological states such as
AD may still be alive. Therefore, the possibility of
restoring the cholinergic phenotype by identifying new
factors that influence cholinergic function would be an
interesting point for further investigation. Some candi-
dates are the BMPs and neurosteroids. Studies by
Lopez-Coviella and colleagues have shown that BMP-9
is a robust factor for induction and maintenance of the
cholinergic phenotype in vitro [60,61], which also syner-
gizes with NGF to enhance neuronal transcriptional
response [30,62]. In addition, neurosteroids such as
estrogen and retinoic acid have also been shown to up-
regulate the cholinergic phenotype in the septal basal
forebrain [63,64].
Taking this into account, future studies could search
for components that up-regulate the cholinergic pheno-
type in the absence of NGF receptors. This may open
new avenues for therapeutic intervention for the treat-
ment of the cholinergic deficit observed in AD.
Methods
Animals
Male Sprague-Dawley rats were maintained with free
access to water and fed with normal rat chow at the Ponti-
ficia Universidad Catolica animal care facilities. Experi-
mental procedures were in accordance with institutional
standards for care and use of laboratory animals.
R a t sw e i g h t i n g2 8 0 - 3 0 0gw e r ea n e s t h e t i z e d( x y l a z i n e
2 mg/ketamine 20 mg i.p. and lidocaine 9% locally
applied on the ears) and positioned in a stereotaxic
apparatus. Coordinates were calculated based on the
Paxinos and Watson atlas of the rat brain [65]. After
surgery, the animals were injected i.p with antibiotic
(enrofloxacine 7.5 mg) and maintained under observa-
tion and temperature control for one hour. For histolo-
gical preparation of brain tissue, rats were transcardially
perfused with 250 ml of 0.9% NaCl, and 250 ml of 4%
paraformaldehyde (PFA) in phosphate buffer. After
extraction, the brain was post-fixed overnight in 4%
PFA, left on 30% sucrose for 24 hours, and coronally
sectioned (40 μm) on a cryostat.
Fimbria-fornix transection
Unilateral axotomy of the septo-hippocampal pathway
was induced by aspirative lesion of the fimbria-fornix, as
has been previously described [66]. In brief, anesthetized
rats were positioned in a stereotaxic apparatus and a
small piece of skull was removed at the stereotaxic coor-
dinates 1.8 mm caudal to the bregma, and 0.0-4.0 mm
lateral to the midline. After excision of the dura, we per-
formed a syringe aspiration of the dorsal fornix-fimbria.
We also used a syringe to aspirate part of the cingulate
and parietal cortices, 3.5 mm ventral from the brain sur-
face. Rats were sacrificed 3-21 days after axotomy.
H2O2 injection in the medial septum
Two μlo f0 . 1MH 2O2 were injected in the septal areas
of two adult rats: 0.35 mm rostral to bregma, 0.5 mm
lateral to midline and 7 mm dorso-ventral. After 72
hours, rats were perfused and brain sections were pre-
pared for immunostaining.
Intracerebroventricular infusion of NGF
Artificial cerebrospinal fluid (ACSF) containing 150 mM
NaCl, 1.8 mM CaCl2,1 . 2m MM g S O 4,2m MK H 2PO4
and 10 mM glucose, pH 7.4 with or without NGF (Alo-
mone Labs, Jerusalem, Israel) at a concentration of 0.2
Table 1 Total number of neurons in the medial septum.
Number of neurons
Brain Hemisphere Left (± SD) Right (± SD) Number of brains considered Number of sections per brain
Lesioned brain 1090 ± 319 (CL) 1103 ± 233 (IPL) 5 3
Healthy brain 1085 ± 137 1057 ± 82 3 3
Neurons from the medial septum, as delineated in Figure 5, of brains from axotomized rats (lesioned brains) and control rats (healthy brains) were labeled with
neurotrace and their number quantified. CL, contralateral to the lesion. IPL, ipsilateral to the lesion.
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brain infusion kit (Alza Corp., Palo Alto, CA), connected
to a model 2002 Alzet osmotic pump (Alza Corp., Palo
Alto, CA), as described previously [6]. The cannulae and
connector tube were filled with ACSF only or with
ACSF plus NGF and attached to a loaded pump. Using
the arm of the stereotaxic apparatus, the cannula was
lowered into the brain at left ventricle coordinates (0.8
mm caudal to bregma, 1.2 mm lateral to midline and
3.5 mm ventral to the brain surface) and finally
anchored to the skull with a screw and glued with den-
tal acrylic. Axotomized rats were infused for 14 days
immediately after axotomy (simultaneous NGF infusion)
or 3 weeks after axotomy (delayed NGF infusion).
AChE enzyme-histochemistry
Serial coronal cryostat sections (40 μm) were collected
in 0.1 M phosphate buffer (pH 7.4), washed in 65 mM
sodium maleate (pH 6.0) and incubated for staining, as
floating sections, for 1 hour at room temperature in
0.05 mg/mL acetylthiocholine iodide, 0.1 tetra-isopro-
pyl-pyrophosphatamide, 0.05 mM potassium ferricya-
nide, 0.3 mM CuSO4, 0.5 mM sodium citrate, and 65
mM sodium maleate (pH 6.0), as described previously
[46].
Figure 6 Effect of intracerebroventricular infusion of NGF on the loss and recovery of the cholinergic phenotype. A,T h e
septohippocampal path was axotomized and NGF-infusion was performed for two weeks. Left, quantification of septal cholinergic neurons in
the lesioned side as compared to the contralateral side in untreated animals (control), lesioned animals (lesion) and lesioned animals brain-
infused with NGF (lesion + NGF sim.). Right, light microscopy of anti-NGF immunohistochemistry showing the wide distribution of infused NGF
and uptake of NGF by septal neurons. Exogenous NGF infused right after axotomy protects cholinergic cells from ChAT-loss. B, The
septohippocampal path was axotomized and 3 weeks after the axotomy (delayed NGF-infusion), NGF was infused for two additional weeks. This
procedure did not protect cholinergic cells from ChAT-loss, contrary to the protection observed with simultaneous infusion. C, Confocal
microscopy of double immunofluorescence against TrkA and ChAT showing the colocalization of these markers in septal neurons 21 days after
axotomy (inferior panel). There are no ChAT-negative cells positive for TrkA, suggesting that neurons cannot respond to NGF 3 weeks post-
axotomy due to down-regulation of NGF receptors.
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ChAT immunohistochemistry was performed as follows:
(i) 15 min incubation in 0.03% H2O2 in 0.1 M Tris-HCl,
150 mM NaCl, pH 7.4 (TBS) to block endogenous per-
oxidase; (ii) 30 min incubation at 4°C with 0.4% Triton-
X100 in TBS; (iii) 1.5 hr incubation at 4°C with 0.2%
Triton-X100, 5% rabbit serum, 5% BSA in TBS; (iv) 48
hr incubation at 4°C with goat anti-ChAT antibody
(Chemicon, CA, USA) diluted 1:300 in TBS plus 0.2%
Triton-X100 and 5% serum; (v) 1.5 hr incubation at
room temperature with biotin-conjugated rabbit anti-
goat IgG (1:300 in TBS; DakoCytomation, CA, USA);
(vi) 1 hr incubation with peroxidase-conjugated avidin
ABC (DakoCytomation, CA, USA), followed by visuali-
zation of peroxidase activity with diaminobenzidine
(DAB, 1 mg/mL) 0.01% H2O2 in TBS.
NGF immunohistochemistry was preceded by 15 min
incubation in 50% ethanol, followed by the same proto-
col already described. Rabbita n t i - N G F( A l o m o n eL a b s ,
Jerusalem, Israel) and rabbit anti-p75 (Upstate, NY,
USA) were used at 1:300 and 1:500, respectively.
Immunofluorescence
Single or double-immunofluorescence was performed in
floating brain sections as follows: (i) 15 min incubation
in TBS; (ii) 15 min incubation in NaBH4 10 mg/mL; (iii)
30 min incubation at 4°C with 0.4% Triton-X100 in
TBS; (iv) 1.5 hr incubation at 4°C in 0.2% Triton-X100,
5% rabbit serum, 5% BSA in TBS; (v) 48 hr incubation
at 4°C with primary antibodies in 0.2% Triton-X100 5%
serum in TBS; (v) 1.5 hr incubation at room tempera-
ture with fluorochrome-conjugated (Molecular Probes,
Oregon, USA) or biotin-conjugated secondary antibodies
(directly labeled antibodies were used 1:100 in TBS;
antibodies amplified with biotin were diluted 1:300 in
TBS), followed by 1.5 hours with fluorochrome-conju-
gated streptavidin (Molecular Probes, Oregon, USA).
Mouse anti-Neu-N, anti-parvalbumin, and rabbit anti-
GFAP (labeling astroglia) antibodies were from Chemi-
con (Temecula, CA, USA). Mouse anti-CD11B (labeling
microglia) was from Serotec, Oxford, UK. Rabbit poly-
clonal anti-OMgp (labeling oligodendroglia) was kindly
provided by Dr. Colman (McGill University, Montreal,
Canada). Polyclonal rabbit anti-cleaved caspase-3 was
purchased from Cell Signaling Technology (Danvers,
MA, USA). Monoclonal anti-p53 was from Santa Cruz
Biotechnologies, CA, USA; polyclonal rabbit anti-TrkA
antibody was kindly provided by Dr. L. Reichardt (Uni-
versity of California, San Francisco, CA, USA).
Neurotrace and Fluorojade C staining
Staining with fluorescent probes such as Neurotrace
(fluorescent Nissl stain; Molecular Probes, Oregon,
USA) and Fluorojade C (specific marker for degenerat-
ing neurons; Chemicon, CA, USA) was performed as
indicated by the manufacturers’ instructions. Briefly,
Neurotrace staining was performed after immunostain-
ing by incubating brain sections for 20 min in a 1:200
dilution of Neurotrace in TBS. Sections were then
rinsed, air-dried and mounted in Mowiol. Fluorojade
staining was performed after Neurotrace as follows:
brain sections were rinsed twice in TBS, re-hydrated for
2 minutes in distilled water and incubated for 10 min-
utes in 0.06% potassium permanganate. Finally, brain
sections were washed for 2 minutes in distilled water
and incubated for 10 minutes in 0.0002% Fluorojade C
solution in 0.1% acetic acid. Sections were immediately
rinsed in distilled water, mounted, air-dehydrated,
cleared with xylene and mounted in Entellan.
Septal cholinergic cell counting
The cholinergic cell count was performed essentially as
described before [46] but modified for rat. Septal choli-
nergic neurons were defined by using anatomical land-
marks in accordance with the rat brain atlas [65]. The
ventral border of the medial septum was defined dorsal
to the anterior commissure, and the rostral beginning
was indicated by the meeting of the body of the corpus
callosum at the midline. The caudal end of the septal
nucleus was defined by the appearance of the fornix and
the midline crossing of the anterior commissure. Four
40-μm-thick coronal sections were examined for each
rat (n = 4 animals per time point), starting 0.7 mm cau-
dal to bregma and 200 μm apart, to avoid counting the
same cell twice. For each section, immunopositive neu-
ronal profiles (labeled with ChAT or p75) were counted
on images digitized on an Olympus BX51 (Tokyo,
Japan) optic microscope (40× objective), equipped with
a CoolSnap-Pro digital camera (Media Cybernetics,
Maryland, USA) and connected to an image analysis sys-
tem based on Image-pro express software, version
5.1.0.12 (Media Cybernetics, Maryland, USA). The pic-
tures were analyzed by using the Sigmascan software
(SPSS; Chicago, IL, USA). The criterion for identifying
ChAT- or p75- immunopositive cells was the appear-
ance of a clear nucleus or, in cases when staining was
too dark, clear neuronal morphology.
Total neuron counts
The anatomical landmark we used to define the medial
septum nucleus (MS) was the same previously described
for septal cholinergic cell counting. Three 40-μm-thick
coronal sections were considered for each rat (n = 5 ani-
mals), starting 0.7 mm caudal to the bregma and 200
μm apart, to avoid counting the same cell twice. The
sections were double-stained with Neurotrace (fluores-
cent Nissl stain; Molecular Probes, Oregon, USA; as
indicated by the manufacturer instructions) and anti-
Neu-N diluted 1:250 and developed with a secondary
antibody conjugated to Alexa 488 fluorochrome. The
Lazo et al. Molecular Neurodegeneration 2010, 5:5
http://www.molecularneurodegeneration.com/content/5/1/5
Page 9 of 12area for counting was defined as a triangle: its base was
ah o r i z o n t a ll i n ec r o s s i n gt h em i d d l ep o i n to ft h el e f t
and right anterior commissures, and its sides were the
anatomical borders of the medial septum, as shown in
Figure 5. Eight pictures of this area (four per side) were
obtained using a confocal microscope with a 63× objec-
tive and scanned with an optical section of 10.3 μm.
The criterion used to define healthy neurons was Neu-
N and/or Neurotrace staining: cells with cytoplasmic
and nucleolar staining, as shown in Figure 3, were
counted as healthy neurons. Other patterns of staining
corresponding to neurons undergoing degeneration
[67,68], such as perinuclear Nissl (or chromatolytic)
staining and eccentric distribution of the nucleus, were
scarcely observed after axotomy (and clearly observed
after H2O2 injection) and were not considered.
Confocal microscopy
Confocal images for counting double-labeled ChAT/p75
neurons or total neurons labeled with Neurotrace and
Neu-N were collected on a Zeiss LSM Pascal 5 (includ-
ing a triple laser module [Arg 458/488/514 nm, HeNe
543 nm, HeNe 633 nm; Carl Zeiss, Thornwood, NY])
connected to an inverted microscope (Axiovert 2000). A
lower objective (20×) was used to have a panoramic
view of the septal nucleus of each brain section and a
higher magnification objective (63×) was used to scan
the total area as described in Figure 5. The images were
analyzed using the SigmaScan software (SPSS, Chicago,
IL, USA).
Data analysis
Comparisons between the axotomized or unlesioned
side of the septum were statistically validated by per-
forming a Student’s t-test to determine significance level
(p < 0.05). The analyses were performed using the sep-
tum contralateral to the lesioned side as a control
(100%).
Additional File 1: Validation of p53 and activated-Caspase 3 as
neurodegeneration markers in the septum. Confocal microscopy of
coronal sections triple-labeled with anti-activated caspase-3, anti-p53 and
Neurotrace (fluorescent Nissl stain) was performed in septa of rats
injected with H2O2 (100 mM) or unlesioned control rats. The unlesioned
brain shows no reactivity for p53 or activated-caspase 3, while in the
H2O2-injected brain there are labeled neurons in the region of injection.
Labeling neurons (Neurotrace-positive cells) with anti-p53 and anti-
activated-caspase 3, validates these antibodies as neurodegeneration
markers. Additional file: descriptions text (including details of how to
view the file, if it is in a non-standard format).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-1326-5-5-
S1.pdf]
Additional File 2: Neurotrace is a specific neuronal marker.
Neurotrace is a specific neuronal stain and does not colocalize with glial
markers. Left, confocal microscopy (scale bar: 500 μm) of sections
double-labeled with Neurotrace and astroglia (top, anti-GFAP), microglia
(center, anti-CD11B), oligodendroglia markers (bottom, anti-OMgp). Right
panel shows inset magnifications (scale bar: 150 μm).
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